

with laterocervical and submandibular lymphadenitis. Total lymph node excision was performed with a good outcome for all patients except 1, who required additional treatment with antimicrobial drugs because the infected lymph node was incompletely excised (4). Additionally, a systemic *M. bohemicum* infection associated with immunodeficiency was reported recently (10). Treatment recommendations for nontuberculous mycobacterial lymphadenitis are outlined in discussions of individual nontuberculous mycobacterium species. Guidelines for localized lymphadenitis caused by any nontuberculous mycobacterium species recommend complete surgical excision of the involved lymph nodes (8). Additional antimicrobial drug therapy is recommended only for patients for whom removal was incomplete (8). Our patient who received combination antimicrobial drug treatment improved, with no relapse.

In summary we report 4 cases of *M. bohemicum* from Austria, a country with 8 million inhabitants. Because these cases were observed in a relatively small country, infections with *M. bohemicum* may be more common than previously thought. More such cases may be discovered as a result of improved microbiologic diagnostic techniques. We believe that *M. bohemicum* should be listed among the species that induce nontuberculous mycobacterial infections.

**Julia Huber,* Elvira Richter,†
Lothar Binder,‡
Matthias Maaß,§ Robert Eberl,*
and Werner Zenz***

*Medical University of Graz, Graz, Austria;

†National Reference Center for Mycobacteria, Borstel, Germany; ‡Elisabethinen Hospital, Linz, Austria; and §University Hospital Salzburg, Salzburg, Austria

DOI: 10.3201/eid1407.080142

References

1. Reischl U, Emler S, Horak Z, Kausova J, Kroppenstedt RM, Lehn N, et

- al. *Mycobacterium bohemicum* sp. nov., a new slow-growing scotochromogenic mycobacterium. *Int J Syst Bacteriol*. 1998;48:1349–55.
2. Torkko P, Suomalainen S, Ivivanainen E, Suutari M, Paulin L, Rudback E, et al. Characterization of *Mycobacterium bohemicum* isolated from human, veterinary, and environmental sources. *J Clin Microbiol*. 2001;39:207–11. DOI: 10.1128/JCM.39.1.207-211.2001
3. Tortoli E, Kirschner P, Springer B, Bartoloni A, Burrini C, Mantella A, et al. Cervical lymphadenitis due to an unusual mycobacterium. *Eur J Clin Microbiol Infect Dis*. 1997;16:308–11. DOI: 10.1007/BF01695636
4. Schulzke S, Adler H, Bar G, Heining U, Hammer J. *Mycobacterium bohemicum*—a cause of paediatric cervical lymphadenitis. *Swiss Med Wkly*. 2004;134:221–2.
5. Palca A, Aebi C, Weimann R, Bodmer T. *Mycobacterium bohemicum* cervical lymphadenitis. *Pediatr Infect Dis J*. 2002;21:982–4. DOI: 10.1097/00006454-200210000-00022
6. Tortoli E, Bartoloni A, Manfrin V, Mantella A, Scarparo C, Bottger E. Cervical lymphadenitis due to *Mycobacterium bohemicum*. *Clin Infect Dis*. 2000;30:210–1. DOI: 10.1086/313600
7. Richter E, Niemann S, Rüscher-Gerdes S, Hoffner S. Identification of *Mycobacterium kansasii* by using a DNA probe (AccuProbe) and molecular techniques. *J Clin Microbiol*. 1999;37:964–70.
8. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med*. 2007;175:367–416. DOI: 10.1164/rccm.200604-571ST
9. Patel JB, Leonard DG, Pan X, Musser JM. Sequence-based identification of *Mycobacterium* species using the MicroSeq 500 16S rDNA bacterial identification system. *J Clin Microbiol*. 2000;38:246–51.
10. Glosli H, Stray-Pedersen A, Brun AC, Holtmon LW, Tonjum T, Chappier A, et al. Infections due to various atypical mycobacteria in a Norwegian multiplex family with dominant interferon-gamma receptor deficiency. *Clin Infect Dis*. 2008;46:e23–7. DOI: 10.1086/525855

Address for correspondence: Julia Huber, Department of General Pediatrics, Division of Infectiology, Medical University of Graz, Auenbruggerplatz 30, 8036 Graz, Austria; email: julia.huber@meduni-graz.at

Pertussis Surveillance in Private Pediatric Practices, France, 2002–2006

To the Editor: In France, pertussis epidemiology has been extensively studied since 1993. Immunization of children with a highly efficacious pertussis whole-cell (Pw) vaccine (Sanofi Pasteur MSD, Lyon, France) for 40 years (since 1966) has reduced the incidence of pertussis. It has been demonstrated that infectious or vaccinal immunity to pertussis wanes with time and that pertussis is no longer a pediatric disease (1–5). Transmission now occurs predominantly from adolescents and adults to unvaccinated newborns.

From 1966 through 1995, primary vaccination against pertussis was administered to children at 3, 4, and 5 months of age, and a booster was given at ≈2 years of age. Since 1995, primary vaccination has been administered at 2, 3, and 4 months of age, and a booster is given at 16–18 months of age. Duration of protection of children immunized with Pw vaccine at these schedules is estimated to be ≈7–9 years (1,5).

In response to the problem of waning immunity, a second pertussis booster immunization at 11–13 years of age was introduced in 1998 (6). Development of pertussis acellular (Pa) vaccines has enabled administration of this booster immunization. The French hospital network surveillance system (Renacoq) was established in 1996 to monitor severe pertussis in infants and the effect of late booster immunizations. A cyclic disease pattern was observed; peaks were noted for 1993, 1997, 2000, and 2005. However, the last peak had a low amplitude; since then a diminution in the proportion of siblings who transmitted the infection to young infants was observed (2). These results could have been caused

by adolescent booster immunizations.

We evaluated whether the duration of immunity induced by Pw vaccine was still similar to the duration estimated in 1993–1994. This surveillance was necessary because antigenic changes in circulating isolates of *Bordetella pertussis* were observed when compared with vaccine strains (7). To achieve this goal, a private pediatric network was set up and data from this surveillance are presented.

From September 2002 through April 2006, 79 pediatricians in France enrolled all infants and children suspected of having pertussis. A standardized data form was completed for age, sex, vaccination data, and source of infection. Biologic confirmation of cases was obtained by using routine laboratory diagnoses, i.e., culture, PCR, or serology. Real-time PCR was performed according to consensus rules (8). Routine serodiagnosis was performed by using purified pertussis toxin and Western blotting according to the method of Guiso et al. (9) because this is the only diagnostic test free for patients in France. Serologic diagnosis was made by detecting antibodies to pertussis toxin in unvaccinated children or in those vaccinated >1 year earlier. Epidemiologic case-patients were defined as those with a cough for 14 days who had contacts with a confirmed case-patient within 4 weeks of the onset of the cough. No

confirmed suspected case-patients had coughs; all were negative for pertussis by biologic diagnosis and did not report contact with a confirmed case-patient.

A total of 383 children were enrolled in the study. However, vaccination status and a biologic diagnosis were available for only 139 children (Table). Forty-seven children had biologically confirmed cases and 92 had nonconfirmed cases. Among children with confirmed cases, only 22 had been vaccinated. At time of disease, the mean \pm SD age of these children was 9.9 ± 2.1 years. This age was similar to the age observed during 1993–1994 (1,5).

The diagnosis for the 92 children suspected of having pertussis was not confirmed biologically. Culture and PCR are used for diagnosis early in the course of pertussis. However, serologic analysis is used later because antibodies are rarely detected before 3 weeks of onset of a cough. More culture and PCR diagnoses were performed for unvaccinated confirmed case-patients than for vaccinated confirmed case-patients. This finding suggests that unvaccinated children were seen by their pediatricians earlier than vaccinated children because the disease was less severe in vaccinated children or that vaccinated children were older than unvaccinated children.

The source of contamination was known for 47% of the confirmed case-patients (Table). This source was either adults (54.4%) or adolescents (41%) who did not receive their second booster immunization or an unvaccinated infant (4.5%). These data are similar to those obtained by the French hospital-based surveillance (2). They also support the strategy started in 2004 of recommending a pertussis booster immunization for adults in contact with children and all healthcare workers who come in contact with infants (10)

In conclusion, this pediatric surveillance confirms the usefulness of following vaccine recommendations for pertussis and of using biologic techniques to confirm a diagnosis. The vaccine strategy recommending a booster vaccination at 11–13 years of age is still in accordance with epidemiologic features observed. Pediatricians should continue this surveillance to evaluate evolution of *B. pertussis* populations and the effect of replacing Pw vaccines with Pa vaccines.

Acknowledgments

We thank the pediatricians of the Association Clinique et Thérapeutique Infantile du Val de Marne and Association Française de Pédiatrie Ambulatoire networks (C. Abt-Nord, D. Allain, R. Asathiany, I. Aubier, C. Bailly, P. Bakhache, N. Baudino, B. Bedouret, G. Beley, M.

Table. Characteristics of confirmed and nonconfirmed pertussis case-patients for whom vaccination status with pertussis whole-cell (Pw) vaccine was known

Characteristic	Vaccinated 4x with Pw vaccine (N = 70)		Unvaccinated (N = 69)	
	Confirmed case-patients (n = 22)	Nonconfirmed case-patients (n = 48)	Confirmed case-patients (n = 25)	Nonconfirmed case-patients (n = 44)
Diagnostic method				
Culture	0†		3*	
PCR	7†		17*	
Serology	13		3	
Epidemiology	2		2	
Age, y	9.9 ± 2.1 †	7.8 ± 3.4	2.3 ± 3.9 †	0.8 ± 2.3
p value for age	0.008		0.0046	
Source of contamination				
Adults	5		7	
Adolescents	4		5	
Infants	1 (unvaccinated)		0	

*p = 0.0009 for PCR and culture for case-patients receiving 4 doses of Pw vaccine versus unvaccinated confirmed case-patients.

†p < 0.0001 by age for case-patients receiving 4 doses of Pw vaccine versus unvaccinated confirmed case-patients.

Benani, E. Boez, F. Bouillot, C. Bourgin, P. Brichon, J. Cabos, C. Calame-Pilczner, F. Ceccato, J. Cheymol, D. Clavel, C. Copin, F. Corrad, L. Cret, B. De Brito, F. De Grenier, P. Deberdt, A. Delatour, V. Derkx, S. Dieu-Osika, M.N.Domalain, M. Dubosc, S. Duriez, C. Duval, N. El Khoury, A. Elbez, J. Elbhar, M.H. Evroux, E. Fournier-Giorno, D. Garel, A. Gasser, B. Gaudin, S. Gissinger, R. Gorge, J. Guittet, M. Guy, G. Hamelin, S. Hauvespre, A. Hayat, M. Hummel, M. Hunin, M. Koskas, C. Lastmann-Lhami, J.P. Lemaire, L. Levesque, M. Lossouarn, P. Lubelski, N. Maamri, V. Medioni, M.O. Mercier-Oger, M.F. Merklen, P. Migault, A. Napoly, B. Nemesin, J.F. Nicolas, S. Orion, A. Pappo, J. Peguet, C. Petit, M. Pilliot, A. Piolet, V. Poulet-Young, J. Robert, C. Romain, M.C. Rondeau, C. Schlemmer, J.M. Thiron, A. Werner, A. Wollner, C. Wollner, and C.Ythier) for their contributions to this study. We also thank M. Boucherat, L. Langlais, M. Oliveira, S. Tortorelli, and S. Veillault for assistance with the study.

Nicole Guiso,*
France de La Rocque,†
Elisabeth Njamkepo,*
Aurelie Lécuyer,†
Corinne Levy,† Olivier Romain,†
Franck Thollot,‡
Véronique Abitbol,§
Benoit Soubeyrand,¶
Robert Cohen,# and the French
Pediatrics Groups Association
Clinique et Thérapeutique
Infantile du Val de Marne and
Association Française de
Pédiatrie Ambulatoire

*Institut Pasteur, Paris, France; †Association Clinique et Thérapeutique Infantile du Val de Marne, Saint Maur des Fossés, France; ‡Association Française de Pédiatrie Ambulatoire, Besançon, France; §GlaxoSmithKline, Marly le Roi, France; ¶Sanofi Pasteur MSD, Lyon, France; and #Centre Hospitalier Intercommunal de Créteil, Créteil, France

DOI: 10.3201/eid1407.071246

References

1. Baron S, Njamkepo E, Grimprel E, Begue P, Desenclos JC, Drucker J, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. *Pediatr Infect Dis J*. 1998;17:412–8. DOI: 10.1097/00006454-199805000-00013
2. Bonmarin I, Levy-Bruhl D, Baron S, Guiso N, Njamkepo E, Caro V, et al. Pertussis surveillance in French hospitals: results from a 10 year period. *Euro Surveill*. 2007; [Epub ahead of print].
3. Gilberg S, Njamkepo E, Du Chatelet IP, Partouche H, Gueirard P, Ghasarossian C, et al. Evidence of *Bordetella pertussis* infection in adults presenting with persistent cough in a French area with very high whole-cell vaccine coverage. *J Infect Dis*. 2002;186:415–8. DOI: 10.1086/341511
4. Wendelboe AM, Njamkepo E, Bourillon A, Floret DD, Gaudelus J, Gerber M, et al. Transmission of *Bordetella pertussis* to young infants. *Pediatr Infect Dis J*. 2007;26:293–9. DOI: 10.1097/01.inf.0000258699.64164.6d
5. Grimprel E, Begue P, Anjak I, Njamkepo E, Francois P, Guiso N. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. *Clin Diagn Lab Immunol*. 1996;3:93–7.
6. Anonymous. Calendrier vaccinal 1998. Avis du conseil supérieur d'hygiène publique de France. *Bulletin Epidemiologique Hebdomadaire*. 1998;15:61–2.
7. Caro V, Hot D, Guigon G, Hubans C, Arrive M, Soubigou G, et al. Temporal analysis of French *Bordetella pertussis* isolates by comparative whole-genome hybridization *Bordetella pertussis*, Finland and France. *Microbes Infect*. 2006;8:2228–35. DOI: 10.1016/j.micinf.2006.04.014
8. Riffelmann M, Wirsing von König CH, Caro V, Guiso N. Nucleic acid amplification tests for diagnosis of *Bordetella* infections. *J Clin Microbiol*. 2005;43:4925–9. DOI: 10.1128/JCM.43.10.4925-4929.2005
9. Guiso N, Grimprel E, Anjak I, Begue P. Western blot analysis of antibody responses of young infants to pertussis infection. *Eur J Clin Microbiol Infect Dis*. 1993;12:596–600. DOI: 10.1007/BF01973637
10. Avis relatif aux recommandations vaccinales contre la coqueluche. Haut Conseil de la Santé Publique. 2008: 1–6 [cited 2008 Apr 14]. Available from http://www.hcsp.fr/hcspi/docspdf/avisrapports/hcspa20080319_coqueluche.pdf

Address for correspondence: Nicole Guiso, Molecular Prevention and Therapy of Human Diseases Unit, National Centre of Reference of Pertussis and other Bordetellosis, Unite de Recherche Associée, Centre National de la Recherche Scientifique 3012, Institut Pasteur, 25 Rue du Dr Roux, 75724 Paris CEDEX 15, France; email: nguiso@pasteur.fr

Avian *Mycoplasma lipofaciens* Transmission to Veterinarian

To the Editor: *Mycoplasma* spp. are well-known pathogens in human and veterinary medicine. Mammals, especially primates and including humans, share similar or even identical *Mycoplasma* spp., which might be commensal or pathogenic (1). Additionally, sporadic infections of immunocompromised persons with *Mycoplasma* spp. that originated from domestic animals have been reported (1); susceptibility in this human population is increased (2,3). *M. phocicerebrale* is the only *Mycoplasma* pathogen of animals that regularly infects humans, causing a disease called seal fingers (1,4). However, we report a human infection with an avian *Mycoplasma* organism.

A clinical trial to investigate the capability of *M. lipofaciens* (strain ML64) (5) to spread horizontally between infected and noninfected turkey poults in an incubator demonstrated airborne transmission of the pathogen within 24 hours (6). During the trial, the veterinarian conducting the study, a 36-year-old man, was monitored for infection. Each day, 2 swabs were taken from both nostrils, starting